04 May 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new and positive pre-clinical data relating to its ExoPr0 stem cell-derived exosome therapy candidate will be presented today at ISCT 2018, a leading scientific conference taking place this week in Montreal, Canada.
30 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be hosting a capital markets event on the Company’s exosome nanomedicine platform on Thursday 17 May 2018. The event, for analysts and institutional investors, will take place at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
19 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new £1.5 million grant award from the UK’s innovation agency, Innovate UK, to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.
10 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that Dr Richard Beckman has joined the Company as Chief Medical Officer. He replaces Dr Julian Howell who has left the Company to pursue another opportunity.
26 March 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update across its research and development programmes.
Positive pre-clinical data published using ReNeuron’s CTX cells in artificial nerve tissue generated as part of a grant-funded collaboration
26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the publication of new positive data in a pre-clinical model of nerve injury which demonstrated comparable nerve regeneration compared to standard of care treatment and a stronger muscle function response.
Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018
26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that positive long-term data from the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability was accepted for a podium presentation given yesterday at the American Heart Association International Stroke Conference 2018 (“ISC 2018”), taking place this week in Los Angeles.
To view the presentation please click here.
23 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced on 5 January 2018 details of a proposed of the existing ordinary share capital of the Company. The Board is pleased to announce that at today’s General Meeting of the Company, Shareholders approved all of the Resolutions set out in the Circular.
11 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today makes the following announcement in connection with the proposed Share Capital Reorganisation of the existing ordinary share capital of the Company announced on 5 January 2018
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a proposed Share Capital Reorganisation of the existing ordinary share capital of the Company.
To view the circular please click here.
For our archived news, click here
